Vincristine + Sirolimus
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kaposiform Hemangioendothelioma (KHE)
Conditions
Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
Trial Timeline
Jun 14, 2017 → Oct 27, 2020
NCT ID
NCT02110069About Vincristine + Sirolimus
Vincristine + Sirolimus is a phase 2 stage product being developed by Pfizer for Kaposiform Hemangioendothelioma (KHE). The current trial status is terminated. This product is registered under clinical trial identifier NCT02110069. Target conditions include Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02110069 | Phase 2 | Terminated |